Follow The Filings

EDSA Edesa Biotech

Edesa Biotech earnings company data as of 4:51 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

2 periods, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Dec EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by EDSA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All EDSA insider trades
  • $233K bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Michael J Brooks President
    Buy
    $3,140 2,000 shares at $1.57 +0.9% to stake
    Traded Feb 26 Filed Mar 11
  2. Pardeep Nijhawan CEO
    Buy
    $6,599 1,000 shares at $6.60 +0.2% to stake
    Traded Mar 10 Filed Mar 10
  3. Pardeep Nijhawan CEO
    Buy
    $39K 10,000 shares at $3.90 +2.5% to stake
    Traded Mar 5 Filed Mar 6
  4. Pardeep Nijhawan CEO
    Buy
    $43K 10,000 shares at $4.26 +2.6% to stake
    Traded Mar 4 Filed Mar 5
  5. Pardeep Nijhawan CEO
    Buy
    $36K 10,000 shares at $3.63 +2.7% to stake
    Traded Mar 3 Filed Mar 4
  6. Pardeep Nijhawan CEO
    Buy
    $6,280 3,000 shares at $2.09
    Traded Mar 2 Filed Mar 3
  7. Pardeep Nijhawan CEO
    Buy
    $99K 50,571 shares at $1.96
    Traded Feb 26–27 Filed Mar 2

Also filed in the last 12 months, not counted as buying or selling: 23 stock grants.

SEC filings

Recent issuer filings from EDGAR, 23 shown.

Filed Form Detail Links
8-K 8.01
SCHEDULE 13G —
SCHEDULE 13D/A —
SCHEDULE 13D/A —
424B5
8-K 1.01,8.01,9.01
424B5
8-K 2.02,9.01
10-Q FORM 10-Q
424B3 FORM 424B3
SCHEDULE 13G —
SCHEDULE 13D/A —
8-K 1.01,3.02,7.01,9.01
8-K 8.01
8-K 5.02,5.07,9.01
SCHEDULE 13G —
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 5.02
8-K 2.02,9.01
10-Q FORM 10-Q

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.